drugset / Trial / NCT00186953

Determination of a Safe Dose of Optison in Pediatric Patients With Solid Tumors

NCT00186953

Phase 1 Completed 14 enrolled St. Jude Children's Research Hospital
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

St. Jude Children's Research Hospital is studying ways to make ultrasound images clearer - to be able to see blood vessels, body structures, and tumors better. Ultrasound uses sound waves to create pictures, allowing doctors and other medical professionals to "see" inside the body. Researchers are studying a contrast agent (like a dye) called Optison™. St. Jude Children's Research Hospital researchers want to learn the best and safest dose of this ultrasound "dye."

Timeline

Start
2002-06
Primary completion
2004-08
Completion
2004-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Optison Diagnostic / imaging agent 0.125 ml
Subject Optison Diagnostic / imaging agent 0.275 ml
Subject Optison Diagnostic / imaging agent 0.425 ml
Subject Optison Diagnostic / imaging agent 0.5 ml